There is currently no clear clinical range for the chances of hepatitis B patients turning negative for liver antigens after antiviral treatment. Generally speaking most hepatitis B virus carriers are lifelong. Antiviral drug therapy for hepatitis B carriers can effectively control virus replication, protect liver function, and prevent the occurrence of hepatitis or hepatocellular carcinoma. For patients who have developed hepatitis, antiviral drug treatment can inhibit the replication of hepatitis B virus, improve liver function damage, and slow down the further development of the disease. However, it is usually not a complete cure. After actively carrying out antiviral treatment, it is necessary to check the viral replication and liver function regularly, which usually can only effectively control the viral replication and achieve better clinical results. It is recommended that patients follow the doctor’s instructions for antiviral treatment, and do not increase or decrease the medication on their own, so as not to delay the treatment of the disease.